BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12679396)

  • 41. Clinical applications of (18)F-FDG in oncology.
    Nabi HA; Zubeldia JM
    J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
    Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
    Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
    Kostakoglu L; Goldsmith SJ
    J Nucl Med; 2003 Feb; 44(2):224-39. PubMed ID: 12571214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of FDG PET.
    Otsuka H; Graham M; Kubo A; Nishitani H
    J Med Invest; 2004 Feb; 51(1-2):14-9. PubMed ID: 15000251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical usefulness of FDG-PET in oncology].
    Sasaki M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Whole-body FDG-PET imaging in the management of patients with cancer.
    Hustinx R; Bénard F; Alavi A
    Semin Nucl Med; 2002 Jan; 32(1):35-46. PubMed ID: 11839068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Fujimoto K; Doi R; Imamura M; Konishi J
    Ann Nucl Med; 2003 Jun; 17(4):261-79. PubMed ID: 12932109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical application of FDG-PET for cancer diagnosis].
    Nakamoto Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Jul; 63(6):285-93. PubMed ID: 12934545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative assessment of tumor metabolism using FDG-PET imaging.
    Weber WA; Schwaiger M; Avril N
    Nucl Med Biol; 2000 Oct; 27(7):683-7. PubMed ID: 11091112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Positron-emission tomography in oncology].
    Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
    Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PET imaging in oncology.
    Bar-Shalom R; Valdivia AY; Blaufox MD
    Semin Nucl Med; 2000 Jul; 30(3):150-85. PubMed ID: 10928381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma.
    Stokkel MP; Draisma A; Pauwels EK
    J Cancer Res Clin Oncol; 2001 May; 127(5):278-85. PubMed ID: 11355142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extranodal manifestations of lymphoma on [¹⁸F]FDG-PET/CT: a pictorial essay.
    Kashyap R; Rai Mittal B; Manohar K; Balasubramanian Harisankar CN; Bhattacharya A; Singh B; Malhotra P; Varma S
    Cancer Imaging; 2011 Nov; 11(1):166-74. PubMed ID: 22123338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [18F FDG PET- applications in oncology].
    Răileanu I; Rusu V; Stefănescu C; Cinotti L
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):638-45. PubMed ID: 12092212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review.
    Sprinz C; Altmayer S; Zanon M; Watte G; Irion K; Marchiori E; Hochhegger B
    PLoS One; 2018; 13(2):e0193140. PubMed ID: 29486008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A shifting landscape: what will be next FDG in PET oncology?
    Inoue T; Oriuchi N; Tomiyoshi K; Endo K
    Ann Nucl Med; 2002 Feb; 16(1):1-9. PubMed ID: 11922202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nuclear imaging of bone tumors: FDG-PET.
    Aoki J; Inoue T; Tomiyoshi K; Shinozaki T; Watanabe H; Takagishi K; Endo K
    Semin Musculoskelet Radiol; 2001 Jun; 5(2):183-7. PubMed ID: 11500164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.